Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Manali A. Bhave, MD
Manali A. Bhave, MD, is an assistant professor in the department of hematology and medical oncology at Emory University School of Medicine.
Articles by Manali A. Bhave, MD
Manali Bhave, MD, discusses the updated results of the MonarchE study of abemaciclib in patients with hormone receptor-positive, HER2-negative, breast cancer.
Latest Updated Articles
Abemaciclib Shows Long-Term IDFS Benefit in HR+, HER2- Breast CancerPublished: March 7th 2022 | Updated:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPublished: June 1st 2022 | Updated: